Web Stats Provided By Google Analytics

Thursday, September 28, 2017

Sanofi and Regeneron Announce Approval of Dupixent (dupilumab) to...

Sanofi and Regeneron Announce Approval of DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union Sanofi and Regeneron Announce Approval of DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union Paris, France and Tarrytown, New York - September 28, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for DupixentA , for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
http://ift.tt/2wYgz3R

No comments:

Post a Comment

Popular Tarrytown Roundup Posts